BridgeBio Pharma, Inc. Quarterly Nonoperating Income (Expense) in USD from Q3 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
BridgeBio Pharma, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2018 to Q3 2024.
  • BridgeBio Pharma, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $27.5M.
  • BridgeBio Pharma, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $98.1M.
  • BridgeBio Pharma, Inc. annual Nonoperating Income (Expense) for 2023 was -$45.9M, a 267% decline from 2022.
  • BridgeBio Pharma, Inc. annual Nonoperating Income (Expense) for 2022 was $27.6M.
  • BridgeBio Pharma, Inc. annual Nonoperating Income (Expense) for 2021 was -$9.82M, a 68.3% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $98.1M $27.5M +$49.3M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $48.8M $100M +$115M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$65.8M -$36.5M -$19.9M -120% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$45.9M $7.09M +$18.4M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 -$64.3M -$21.8M -$10.7M -96.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$53.6M -$14.6M -$92.2M -119% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $38.6M -$16.6M +$11.1M +40.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $27.6M -$11.3M -$24.7M -185% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 $52.2M -$11.1M +$440K +3.82% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $51.8M $77.6M +$85.7M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$33.9M -$27.7M -$24.1M -673% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$9.82M $13.3M +$20.9M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 -$30.7M -$11.5M -$1.29M -12.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$29.4M -$8.06M +$3.59M +30.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$33M -$3.58M -$1.98M -124% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$31M -$7.54M -$2.02M -36.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 -$29M -$10.2M -$4.1M -66.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$24.9M -$11.6M -$6.63M -132% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$18.3M -$1.6M +$4.09M +71.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$22.3M -$5.51M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-25
Q3 2019 -$6.13M -$5.51M -886% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$5.02M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$5.68M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q3 2018 -$622K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.